Eli Lilly announced the availability of Humalog Junior KwikPen (insulin lispro injection) 100 Units/mL for the treatment of type 1 or type 2 diabetes

Humalog Junior KwikPen, a prefilled, disposable half-unit pen, was initially approved by the Food and Drug Administration (FDA) in June 2017. The Humalog Junior KwikPen is lighter and shorter than other half-unit insulin pens, offering an option for patients who prefer a prefilled pen formulation and require half-unit dosing. Patients may include those with insulin sensitivity or older adults for whom rounding to a whole-unit dose is not adequate. 

Related Articles

Prior to Humalog Junior KwikPen, patients could only administer half-units of insulin with a pen through a resusable pen device, which required removing and loading cartridges. Now, patients who take small doses (≤30 Units at mealtime) of Humalog U-100 (insulin lispro injection) can make adjustments in 0.5 Unit increments. 

Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Humalog Junior KwikPen is available as 3mL prefilled pens in 5-count packages. 

For more information call (800) 545-5979 or visit Humalog.com.